Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
DRMA
$1.21
$
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
Next Earnings
2026-02-25
Beta
0.545
Average Volume
Market Cap
Last Dividend
CIK
0001853816
ISIN
US2498455045
CUSIP
249845504
CEO
Gerald T. Proehl
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
8
IPO Date
2021-08-13
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office | This patent grant follows the Company's U.S. issued patent, covering its Spongilla technology combination as a method to topically treat acne Dermata expects to launch a new once-weekly, over-the-counter (OTC) acne treatment system, incorporating its Spongilla technology, in the middle of 2026, first in the U.S. Over 3.3 million people are diagnosed with acne in Australia SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 20, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced the Australian Patent Office has granted its patent application for its Spongilla technology combination as a method for treating acne. The patent, entitled "Compositions and methods for the treatment of skin conditions" (Australian Patent No. | Accesswire | 2026-01-20 08:05:00 |
| Stock Market Today: S&P 500, Dow Jones Futures Trade Mixed Amid Blip In Santa Claus Rally—Boeing, Freeport-McMoRan, Fonar In Focus | U.S. stock futures swung between gains and losses on Tuesday after Monday's declines. Futures of major benchmark indices were mixed. The Santa Claus rally, which began on Dec. 24 last week, seems to have resumed gains after a day of losses on Monday. | Benzinga | 2025-12-30 05:21:38 |
| Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday | U.S. stock futures mixed on Tuesday, potential stocks to watch: TEN Holdings up 17%, Fonar up 24%, CapsoVision down 11%. | Benzinga | 2025-12-30 00:54:07 |
| Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules | $4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESS Newswire / December 29, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced the closing of its previously announced private placement for the issuance and sale of an aggregate of 2,022,062 shares of common stock (or pre-funded warrants in lieu thereof), series C warrants to purchase up to 2,022,062 shares of common stock and short-term series D warrants to purchase up to 2,022,062 shares of common stock at a purchase price of $2.04 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants priced at-the-market under the rules of the Nasdaq Stock Market. The series C warrants and the series D warrants have an exercise price of $2.04 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants. | Accesswire | 2025-12-29 16:05:00 |
| Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules | $4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESS Newswire / December 24, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,022,062 shares of common stock (or pre-funded warrants in lieu thereof), series C warrants to purchase up to 2,022,062 shares of common stock and short-term series D warrants to purchase up to 2,022,062 shares of common stock at a purchase price of $2.04 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under the rules of the Nasdaq Stock Market. The series C warrants and the series D warrants will have an exercise price of $2.04 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants. | Accesswire | 2025-12-24 08:00:00 |
| A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity | SAN DIEGO, CA / ACCESS Newswire / December 4, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced that it will soon reveal its new brand name for its over-the-counter ("OTC") skincare business representing its evolution toward a more direct, science-first era of dermatologic innovation. While the name remains confidential until the formal unveiling, the Company is offering a first look at the mission and essence driving this new identity-one created specifically for the community of skincare consumers who expect more from their products, their science, and the companies behind them. | Accesswire | 2025-12-04 08:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13D/A | 2026-02-23 | 2026-02-23 | View Filing |
| SC 13G/A | 2026-02-18 | 2026-02-18 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-09 | 2026-02-09 | View Filing |
| 8-K | 2026-02-03 | 2026-02-03 | View Filing |
| SC 13D/A | 2026-02-02 | 2026-02-02 | View Filing |
| EFFECT | 2026-01-29 | 2026-01-30 | View Filing |
| 424B3 | 2026-01-29 | 2026-01-29 | View Filing |
| 8-K | 2026-01-27 | 2026-01-27 | View Filing |
| 424B5 | 2026-01-27 | 2026-01-27 | View Filing |
| S-3 | 2026-01-22 | 2026-01-22 | View Filing |
| SC 13D/A | 2026-01-08 | 2026-01-08 | View Filing |
| D | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| SC 13G | 2026-01-02 | 2026-01-02 | View Filing |
| SC 13G | 2025-12-30 | 2025-12-30 | View Filing |
| 4 | 2025-12-29 | 2025-12-29 | View Filing |
| 4 | 2025-12-29 | 2025-12-29 | View Filing |
| 8-K | 2025-12-29 | 2025-12-29 | View Filing |
| 8-K | 2025-11-18 | 2025-11-17 | View Filing |
| 10-Q | 2025-11-14 | 2025-11-14 | View Filing |
| 8-K | 2025-11-14 | 2025-11-14 | View Filing |
| 8-K | 2025-11-07 | 2025-11-07 | View Filing |
| 424B5 | 2025-11-07 | 2025-11-07 | View Filing |
| 8-K | 2025-09-17 | 2025-09-17 | View Filing |
| 8-K | 2025-09-10 | 2025-09-10 | View Filing |
| 8-K | 2025-08-25 | 2025-08-25 | View Filing |
| SC 13G | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-13 | 2025-08-13 | View Filing |
| 8-K | 2025-08-13 | 2025-08-13 | View Filing |
| 8-K | 2025-07-30 | 2025-07-30 | View Filing |
| 8-K | 2025-07-16 | 2025-07-15 | View Filing |
| 8-K | 2025-07-07 | 2025-07-07 | View Filing |
| 8-K | 2025-06-05 | 2025-06-05 | View Filing |
| ARS | 2025-06-02 | 2025-06-02 | View Filing |
| DEFA14A | 2025-06-02 | 2025-06-02 | View Filing |
| DEF 14A | 2025-06-02 | 2025-06-02 | View Filing |
| PRE 14A | 2025-05-23 | 2025-05-23 | View Filing |
| 8-K | 2025-05-21 | 2025-05-21 | View Filing |
| 8-K | 2025-05-16 | 2025-05-16 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| 8-K | 2025-05-14 | 2025-05-14 | View Filing |
| 10-Q | 2025-05-14 | 2025-05-14 | View Filing |
| SC 13G/A | 2025-05-09 | 2025-05-09 | View Filing |
| EFFECT | 2025-04-24 | 2025-04-24 | View Filing |
| 424B3 | 2025-04-23 | 2025-04-23 | View Filing |
| S-3 | 2025-04-15 | 2025-04-15 | View Filing |
| 8-K | 2025-04-15 | 2025-04-15 | View Filing |
| SC 13D/A | 2025-04-07 | 2025-04-07 | View Filing |
| SC 13D/A | 2025-04-03 | 2025-04-03 | View Filing |
| 8-K | 2025-03-28 | 2025-03-28 | View Filing |
| 8-K | 2025-03-27 | 2025-03-27 | View Filing |
| 8-K | 2025-03-25 | 2025-03-25 | View Filing |
| 8-K | 2025-03-17 | 2025-03-17 | View Filing |
| 10-K | 2025-03-17 | 2025-03-17 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13D/A | 2025-02-13 | 2025-02-13 | View Filing |
| EFFECT | 2025-02-06 | 2025-02-06 | View Filing |
| 424B3 | 2025-02-05 | 2025-02-05 | View Filing |
| D/A | 2025-02-04 | 2025-02-04 | View Filing |
| S-3 | 2025-01-30 | 2025-01-30 | View Filing |
| SC 13G | 2025-01-28 | 2025-01-28 | View Filing |
| D | 2025-01-28 | 2025-01-28 | View Filing |
| SC 13D/A | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 8-K | 2025-01-23 | 2025-01-23 | View Filing |
| 8-K | 2025-01-21 | 2025-01-21 | View Filing |
| 4 | 2025-01-14 | 2025-01-14 | View Filing |
| 4 | 2025-01-14 | 2025-01-14 | View Filing |
| 4 | 2025-01-14 | 2025-01-14 | View Filing |
| 4 | 2025-01-14 | 2025-01-14 | View Filing |
| 4 | 2025-01-14 | 2025-01-14 | View Filing |
| 4 | 2025-01-14 | 2025-01-14 | View Filing |
| 4 | 2025-01-14 | 2025-01-14 | View Filing |
| 4 | 2025-01-14 | 2025-01-14 | View Filing |
| 4 | 2025-01-14 | 2025-01-14 | View Filing |
| 4 | 2025-01-14 | 2025-01-14 | View Filing |
| 4 | 2025-01-14 | 2025-01-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| 8-K | 2024-11-14 | 2024-11-13 | View Filing |
| 10-Q | 2024-11-13 | 2024-11-13 | View Filing |
| D | 2024-09-27 | 2024-09-27 | View Filing |
| EFFECT | 2024-09-25 | 2024-09-25 | View Filing |
| 424B3 | 2024-09-24 | 2024-09-24 | View Filing |
| S-3 | 2024-09-19 | 2024-09-19 | View Filing |
| 8-K | 2024-09-17 | 2024-09-17 | View Filing |
| S-8 | 2024-08-07 | 2024-08-07 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Neural Forcast | 72.06% | 1 | 684 | 0.03 | 0.07 | 92.22 |
| Market Cycle | 42.28% | 1 | 338 | 0.02 | 0.05 | 62.43 |
| Volume Gap | 16.44% | 1 | 703 | 0.01 | 0.02 | 36.6 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | x |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |